AgomAb Therapeutics raises $40.5 million in Series B+ funding
AgomAb Therapeutics is a biopharmaceutical organization developing agonist antibodies to regenerate damaged tissue. It mainly develops antibodies for fibrosis, inflammation, autoimmunity and degenerative diseases, and applies the products to clinical trials. A few days ago, Agomab Therapeutics announced the completion of the B+ round of financing and received $40.5 million in funding support. Pfizer led […]
AgomAb Therapeutics raises $40.5 million in Series B+ funding Read More »